We take on some of the toughest cancers with a single goal in mind: to help more patients around the world lead fuller, longer lives. We pioneer research across oncology. Developing new technologies and medicines has allowed us to reimagine patient treatments for solid tumours and blood cancers.
Our scientific research has led to critical discoveries in the treatment of blood cancer. Building upon our strong commitment to patients and existing leadership, we are driving innovation in cancer research and treatment for both blood cancers and solid tumours.
Our robust portfolio is comprised of treatments and an advancing pipeline designed to tackle some of the most difficult-to-treat cancers.
We are focusing on finding answers that transform the way cancer is treated. We want to find better, longer-lasting results across blood cancers and solid tumours. Our culture of curiosity drives us to uncover new solutions.
Blood cancer is a disease that impacts blood-forming tissues (such as bone marrow) and inhibits the body's ability to fight off infection. Leukemia, lymphoma, and myeloma are the most common forms of blood cancer that are seen in patients.
We are advancing an innovative solid tumour portfolio that tackles some of the most difficult-to-treat cancers.
Global CLL Community Insights, a report with CLLAN, highlighting patient wellbeing and communication needs.
You will be leaving your country’s AbbVie site and will be redirected to another country’s website. The AbbVie’s web site to where you will be redirected is exclusively designed for residents of particularly one or various countries, as announced in such web site. As a result, the website where you will be directed may contain pharmaceutical products information or other information that is not approved in other countries, regions or even in your country or territory of reference. If you live in a country other than those to which the site is directed, please contact your local AbbVie affiliate for the correct information on the products of your country of residence.